早期乳腺癌风险分析的进展:从基因病理学到分子技术
Carlo Pescia1,2, Elena Guerini-Rocco1,3, Giuseppe Viale1
1Division of Pathology, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Cancers
|November 25, 2023
概括
这项研究详细介绍了早期乳腺癌 (BC) 风险分层策略. 它旨在指导病理学家通过将传统组织学与先进的分子和奥米克方法相结合,以获得更好的患者结果.
科学领域:
- 在瘤学瘤学.
- 病理学 病理学 病理学
- 基因组学就是基因组学.
背景情况:
- 早期乳腺癌 (BC) 需要精确的风险分层来进行有效的临床管理.
- 目前关于早期BC风险分层的指导方针往往是不够的.
- 组织病理学特征和生物标志物对于预测患者结果至关重要.
研究的目的:
- 提供当前早期乳腺癌风险分层策略的全面概述.
- 为基因病理学家和分子病理学家提供实用指南.
- 突出了对标准化方法和综合病理模型的需求.
主要方法:
- 审查传统的组织病理学标准 (瘤大小,等级,淋巴结状况等). ) 的情况.
- 关键生物标志物的评估,包括激素受体,HER2和BRCA1/2.2.
- 通过基因表达分析和"奥米克"技术 (组织和液体活检) 探索分子亚型.
主要成果:
- 传统的组织学因素仍然是显著的预后指标.
- 分子亚型为个性化治疗决策提供了宝贵的见解.
- "奥米克"技术扩大了早期BC风险评估的能力.
结论:
- 对于早期BC风险分层的综合病理模型,需要标准化的方法.
- 结合组织学,生物标志物和分子数据对于全面的风险评估至关重要.
- 本综述旨在加强早期乳腺癌患者的临床决策.
更多相关视频
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
12.6K
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
16.6K
相关概念视频
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Cancer Survival Analysis
356
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
356
